BI 3034701
Alternative Names: BI-3034701; Triple GLP-1/GIP/NPY2 agonist - Boehringer Ingelheim/GubraLatest Information Update: 16 Sep 2026
At a glance
- Originator Boehringer Ingelheim; Gubra
- Developer Boehringer Ingelheim
- Class Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists; Neuropeptide Y2 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 24 Aug 2026 Phase-I clinical trials in Obesity (In volunteers) in Hungary (SC) (NCT07708493)
- 10 Aug 2026 Boehringer Ingelheim plans a phase I trial for Obesity in Germany (SC), in September 2026 (NCT07754474) (CTIS2026-526090-42-00)
- 21 Jul 2026 Phase-I clinical trials in Obesity in Japan (SC) (NCT07693231)